Nonvenereal Syphilis Treatment Market Share

  • Report ID: 3569
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Nonvenereal Syphilis Treatment Market Share

Middle East and Africa Forecast

The Middle East and Africa nonvenereal syphilis treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market can be attributed majorly to the existence of nonvenereal syphilis in regions of West Africa, the Mediterranean, and the Sahara owing to the lack of sanitization as well as the hot and humid climate. Moreover, the rising awareness of syphilis infections, along with its increasing prevalence is further expected to boost the market growth in this region. As per projections over 10 million people are infected with syphilis worldwide with the majority of these infected people found in sub-Saharan Africa and Asia. In African regions, especially in remote regions of Africa, the living conditions of the Africans in areas such as the Kimberley are considered to be conducive to the spread of Treponema species, hence it is expected that the market in this region will mark growth in the projected years.

APAC Market Statistics

The Asia Pacific nonvenereal syphilis treatment market, amongst the market in all the other regions, is projected to hold the second largest share in the projected years. The market growth in the projected years majorly includes the prospering travel and tourism, sex industry, migration of workers, and poor control measures as well as the rising emergence of syphilis, bejel, yaws, and pinta as a severe public health issue in underdeveloped & developing countries of Asia, South Asia, and the Western Pacific islands. The travel and tourism industry which contributed nearly USD 143 billion to the GDP in Southeast Asia in 2021, has its own pros and cons. Tourism not also attracts tourists but also results in the transmission of various pathogens from one country to another. Thus, the increasing awareness campaigns as well as the growing government spending on the development of proper diagnostic facilities together with rising investment in drug development to curb the spread of such diseases in middle and low-income countries is further expected to escalate the regional market growth.

North American Market Forecast

Furthermore, the market in North America, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2036. The growth of the market can be attributed majorly to the gradual spread of bejel on islands of the region such as in Cuba, as well as increasing government initiatives to curb the spread of Treponema pallidum subsp. endemicum (TEN) along with the development of rapid diagnostic tests (RDTs) that can better distinguish an active infection of syphilis, bejel, or yaws to facilitate early treatment to the patients is expected to boost the nonvenereal syphilis market in the region in the projected years.

Research Nester
Nonvenereal Syphilis Treatment Market Regional
Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3569
  • Published Date: Jul 24, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of nonvenereal syphilis treatment is assessed at USD 329.34 Million.

The nonvenereal syphilis treatment market size was over USD 304.92 Million in 2023 and is expected to reach USD 923.74 Million by the end of 2036, growing at around 8.9% CAGR during the forecast period i.e., between 2024-2036. The rising cases of bejel as well as the increasing augmentation of infectious diseases are the major growth factors driving the growth of the market.

Middle East and Africa is likely to dominate majority industry share by 2036, attributed to existence of nonvenereal syphilis in regions of West Africa, the Mediterranean, and the Sahara propelled by lack of sanitization as well as the hot and humid climate.

Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Cipla Limited
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample